Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launched these strengths of lenalidomide.

• Uber Gets Slapped with £250 Million Lawsuit from London’s Black Cab Drivers 
• Dabur India Shares Rally 5% on Strong Q4 Earnings 
• Adani Enterprises Shares Fall 1% on Weak Q4 Earnings 
• Avaada Energy Receives Rs 1,190 Crore Loan for Solar Project 
• GE T&D India Shares Hit 52-Week High on Securing New Orders 

In the above strengths of lenalidomide, capsules are prescribed in adults to treat multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.